# A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy

> **NCT06269393** · PHASE3 · COMPLETED · sponsor: **Peking University People's Hospital** · enrollment: 53 (actual)

## Conditions studied

- Thyroid Associated Ophthalmopathy

## Interventions

- **DRUG:** Placebo
- **DRUG:** IBI311

## Key facts

- **NCT ID:** NCT06269393
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-01
- **Primary completion:** 2025-04-03
- **Final completion:** 2025-07-03
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06269393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06269393, "A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06269393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*